IPO
Probiodrug AG announced its financial results for the twelve-month period ending December 31, 2018, prepared in accordance with German GAAP and on a voluntary basis, in accordance with IFRS as endorsed by the European Union.
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
GeoVax Labs, Inc., a biotechnology company developing human vaccines, announced its financial results for the year ended December 31, 2018.
Epigenomics AG announced the financial results for the year ended December 31, 2018.
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
Genfit, with offices in Lille, France and Cambridge, Mass., launched its initial public offering (IPO) on the Nasdaq on March 27. Dean Hum, chief operating officer of Genfit, took time out to speak with BioSpace about the company, the IPO and elafibranor.
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
The world-renowned HGH Infrared Systems is developing its brand image and communication strategy to better reflect its position as a global leader in the optronics market.
Soligenix, Inc announced its recent accomplishments and financial results for the year ended December 31, 2018.
Immunicum AB announced that members of the management team will attend and present at upcoming conferences in March and April.
PRESS RELEASES